Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | KDM1A | O60341 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7221738 | 0.98 | SMN1; SMN2 (0.52) | L3MBTL1GLAHTTTSHRALOX15 | |
| Hydrochloric Acid SCHEMBL15286271 | 0.98 | L3MBTL1 (0.52) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL19993212 | 0.93 | GLA (0.50) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL25676935 | 0.83 | LMNA (0.53) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL1226363 | 0.80 | ATM (0.50) | L3MBTL1HTTTSHRSMN1; SMN2ALDH1A1 | |
| SCHEMBL22681243 | 0.80 | — | — | |
| SCHEMBL24322565 | 0.80 | HTT (0.56) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL13135936 | 0.80 | HTT (0.52) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL7385455 | 0.80 | GLA (0.57) | L3MBTL1GLAHTTTSHRALOX15 | |
| SCHEMBL3753324 | 0.80 | L3MBTL1 (0.64) | L3MBTL1GLAHTTTSHRALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2023-07-13 | — | — | US | disclosed |
| WO-2023114428-A1 | HETEROCYCLE DERIVATIVES FOR THE TREATMENT OF DISEASE | Vir Biotechnology, Inc. (US) | 2023-06-22 | — | — | WO | disclosed |
| WO-2023073600-A1 | COMPOSITIONS FOR PREVENTING OR TREATING IDIOPATHIC PULMONARY FIBROSIS (IPF) | CHONG KUN DANG PHARMACEUTICAL CORP. (KR) | 2023-05-04 | — | — | WO | disclosed |
| US-11590116-B2 | Substituted pyridines and methods of use | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-02-28 | — | — | US | disclosed |
| EP-3898631-B1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | HOFFMANN LA ROCHE (CH) | 2023-01-18 | — | — | EP | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | Psomagen Inc. (US) | 2022-04-21 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| CN-113195497-A | Novel imidazopyrazine derivatives | 豪夫迈·罗氏有限公司 | 2021-07-30 | — | — | CN | disclosed |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | Epizyme, Inc. | 2021-07-15 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | TANABE SEIYAKU CO., LTD. (JP) | 2009-03-12 | — | — | US | disclosed |
| US-7473688-B2 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-01-06 | — | — | US | disclosed |
| US-20080176844-A1 | Pharmacokinetically Improved Compounds | SURFACE LOGIX, INC. | 2008-07-24 | — | — | US | disclosed |
| US-20080176844-A1 | Pharmacokinetically Improved Compounds | SURFACE LOGIX, INC. | 2008-07-24 | — | — | US | disclosed |
| WO-2008011478-A2 | METHODS FOR TREATING CHRONIC PAIN USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS | ALLERGAN, INC. (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2007046548-A1 | PYRAZOLO[1,5-A]PYRIMIDINE COMPOUNDS AS CANNABINOID RECEPTOR ANTAGONISTS | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-04-05 | — | — | US | disclosed |
| WO-2006089276-A2 | PHARMACOKINETICALLY IMPROVED COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
| WO-2006089275-A2 | METHODS OF MAKING PHARMACOKINETICALLY IMPROVED COMPOUNDS COMPRISING FUNCTIONAL RESIDUES OR GROUPS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAID COMPOUNDS | SURFACE LOGIX, INC. (US) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176844-A1 | Pharmacokinetically Improved Compounds | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC7A1, HRH4 | L3MBTL1 2405/4885GLA 4803/4885HTT 661/4885 |
| US-20090069298-A1 | Pyrazolo[1,5-A]Pyrimidine Compounds | RECQL, QTRT1, DPYD | L3MBTL1 3941/4885GLA 3987/4885HTT 2012/4885 |
| US-20070078122-A1 | Indolobenzazepine HCV NS5B inhibitors | HTR3C, IDO1, HTR3B | L3MBTL1 4524/4885GLA 4705/4885HTT 3177/4885 |
| US-20220122691-A1 | HtrA Inhibitors and CagA Inhibitors and Use Thereof | HTRA1, GIPR, HPN | L3MBTL1 2569/4885GLA 2219/4885HTT 70/4885 |
| US-20230218597-A1 | SUBSTITUTED PYRIDINES AND METHODS OF USE | ALK, ACVR1, ACVR2A | L3MBTL1 2150/4885GLA 1811/4885HTT 4819/4885 |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | L3MBTL1 2707/4885GLA 1786/4885HTT 4404/4885 |
| US-20210213014-A1 | METHODS OF USING EHMT2 INHIBITORS IN IMMUNOTHERAPIES | EHMT2, BHMT2, BHMT | L3MBTL1 2881/4885GLA 3740/4885HTT 849/4885 |
| US-11590116-B2 | Substituted pyridines and methods of use | ALK, ACVR1, ACVR2A | L3MBTL1 2150/4885GLA 1811/4885HTT 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.